Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Non-Deal Roadshow (October 2021)
42 slides from Island Pharmaceuticals's roadshow presentation, Oct 11, 2021
Slide 1: ASX Announcement: Updated Investor Presentation
CONFIDENTIAL 11 October 2021 ASX Announcement For personal use only Updated Investor Presentation MELBOURNE Australia, 11 October 2021: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to share its latest investor presentation. In the
Slide 2: Solving Urgent Viral Disease Threats
For personal use only SOLVING URGENT VIRAL DISEASE THREATS (ASX: ILA) October 2021 ISLAND PHARMACEUTICALS LIMITED 1 Investor INVESTOR Presentation PRESENTATION –– October 2021 OCTOBER 2021
Slide 3: Disclaimer
For personal use only DISCLAIMER This presentation has been prepared by Island Pharmaceuticals Limited views on its future performance or condition. Actual results could differ No representation, warranty or assurance (express or implied) is given (ABN 641 183 842) (Company or Island Pharmaceuticals
Slide 4: Company Overview
For personal use only COMPANY OVERVIEW ISLAND PHARMACEUTICALS LIMITED 3 Investor INVESTOR Presentation PRESENTATION –– October 2021 OCTOBER 2021
Slide 5: Island at a Glance
For personal use only ISLAND AT A GLANCE Island Pharmaceuticals (ASX: ILA) is a mid clinical-stage drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases Island’s drug Island repurposing Initial focus is Pharmaceuticals strategy on mosquito liste
Slide 6: Solving Urgent Viral Disease Threats
For personal use only SOLVING URGENT VIRAL DISEASE THREATS World bank $10 Trillion loss in GDP JAMA Network 2020 - 21 IMF $28 Trillion $16 Trillion ** Cost Estimates Mar 2020 Sep 2020 Oct 2020 Aug 2021 3.26 million cases 4,220,696 deaths Deaths 233,000 deaths ISLAND PHARMACEUTICALS LIMITED * Sources
Slide 7: Drug Repurposing Market
For personal use only DRUG REPURPOSING MARKET Advantages of a drug The global market repurposing approach for for drug repurposing antiviral drug discovery will grow from nearly $24.4 billion in • Low cost and less time- 2015 to nearly $31.3 consuming Bringing a new • Possibility to go directly to m
Slide 8: The Benefits of Drug Repurposing
For personal use only THE BENEFITS OF DRUG REPURPOSING ISLAND PHARMACEUTICALS LIMITED 7 Investor INVESTOR Presentation PRESENTATION –– October 2021 OCTOBER 2021
Slide 9: ISLA-101 Repurposed Drug Dramatically Reduces Development Time, Risk and Cost
For personal use only ISLA-101 REPURPOSED DRUG DRAMATICALLY REDUCES DEVELOPMENT TIME, RISK AND COST Strong regulatory Speed to market ISLA-101, Demonstrated Capitalising on history and & early revenue originally a cancer as safe in humans millions spent acceptance potential drug Originally identifie
Slide 10: Key Collaborations & Alliances
For personal use only KEY COLLABORATIONS & ALLIANCES SUPPORTING FUTURE PIPELINE DEVELOPMENT Research Collaboration Agreement to screen thousands of known molecules against host targets building upon the Fenretinide (ISLA-101) discovery sourced from these laboratories that the Company has licensed fo
Slide 11: Initial Collaboration
For personal use only INITIAL COLLABORATION LICENSED FOR USE AGAINST FLAVIVIRUSES AND PIPELINE EXPANSION Monash University • Isla US initially licensed intellectual property (IP) created by Monash University. IP was produced as part of a research project undertaken by Monash University that led to a
Slide 12: Recently Signed Collaboration
For personal use only RECENTLY SIGNED COLLABORATION ACCELERATE PIPELINE DEVELOPMENT On 23 August 2021 Island Pharmaceuticals (ASX: ILA) announced a Anti-Viral Molecule Screening Collaboration with Griffith University. • The new drug research collaboration focuses on repurposing small molecules with
Slide 13: Board, Management & Scientific Board
For personal use only BOARD, MANAGEMENT & SCIENTIFIC BOARD EXTENSIVE EXPERTISE IN DRUG REPURPOSING AND DEVELOPMENT, INFECTIOUS DISEASES AND COMMERCIAL TRANSACTIONS. MANAGEMENT TEAM & BOARD OF DIRECTORS Dr. David Foster Dr. Anna Lavelle Mr. Al Hansen Dr. Paul MacLeman Dr. David Brookes CEO & Executiv
Slide 14: Corporate Snapshot
For personal use only CORPORATE SNAPSHOT ISSUED CAPITAL Price ILA.ASX Shares issued in IPO 30,000,000 Prior Shares on issue 50,968,468 50,968,468 Price (AUD) Total number of shares on issue 80,968,468 $0.50 MARKET CAPITALISATION $0.45 IPO price (13th April 2021) $0.25 $0.40 Share price (as at 30 Sep
Slide 15: ISLA-101
For personal use only ILSA-101 ISLAND PHARMACEUTICALS LIMITED 14 Investor INVESTOR Presentation PRESENTATION –– October 2021 OCTOBER 2021
Slide 16: ISLA-101: Bringing Its Platform in a Pill to Market
For personal use only ISLA-101 BRINGING ITS PLATFORM IN A PILL TO MARKET Island has repurposed ISLA-101, Warming global an antiviral oral drug to climates are treat mosquito-borne accelerating the viruses (e.g. dengue presence of mosquito- fever / Zika) and borne viruses that can intends to complete
Slide 17: Key Strengths
For personal use only KEY STRENGTHS Initially targeting Drug repurposing Phase II Promising results Commercial Highly dengue diseases strategy ready asset to date upside experienced team with unmet need Targeting diseases, Lead compound, Repurposing can Results in Potential ‘platform Experienced Boa
Slide 18: Why Dengue Diseases?
For personal use only WHY DENGUE DISEASES? SIGNIFICANT UNMET NEED FOR DISEASE WITH INCREASING INCIDENCE Significant unmet need (3.9 billion people at risk*) Increasing spread to US, EU and Australia ISLA-101 has both therapeutic and prophylactic potential Strong animal and human model results First
Slide 19: Mosquito Borne Diseases
For personal use only MOSQUITO BORNE DISEASES MORE PATIENTS, HIGH COSTS, POTENTIALLY A LIFETIME OF ISSUES FOR PATIENTS Can result in life Primary target Dengue fever threatening conditions Mosquito-borne 390m* flaviviruses Haemorrhagic fever West Nile virus Estimated global Shock syndrome cases per
Slide 20: Flaviviruses Becoming Global
For personal use only FLAVIVIRUSES BECOMING GLOBAL WARMING GLOBAL CLIMATES ARE EXPANDING SPREAD BEYOND THE TROPICS* Flaviviruses are spreading outside the tropics: •1 Florida, US •2 Mediterranean, EU West Nile Japanese Encephalitis •3 QLD, Australia West Nile 2 virus Growing issue for Tropic of Canc
Slide 21: Limited Available Solutions
For personal use only LIMITED AVAILABLE SOLUTIONS HIGHLY PREVALENT DISEASES WITH UNMET MEDICAL NEED Deformities in babies from mothers with Dengue Yellow Japanese Zika West Nile Zika Virus fever fever Encephalitis Viral diseases are a Worldwide 390 Up to n/a 130,000 70,000 leading cause of prevalenc
Slide 22: ISLA-101 Prevents Viral Replication
For personal use only ISLA-101 PREVENTS VIRAL REPLICATION ISLA-101 INHIBITS PROPAGATION OF FLAVIVIRUSES* • To replicate, the virus needs to Viral importation hijack the nucleus of the host cell Viral export • Studies demonstrated ISLA-101 prevents this so prevents virus replication • Same mechanism
Slide 23: ISLA-101 Broad Activity Evident
For personal use only ISLA-101 BROAD ACTIVITY EVIDENT DEMONSTRATED ACTIVITY AGAINST FLAVIVIRUSES IN MULTIPLE MODELS OF INFECTION Dengue 1-4 • In in-vitro models using fresh human cells, ISLA-101 has demonstrated broad anti-viral activity Zika • In animal models, ISLA-101 is protective in dengue feve
Slide 24: Safety Profile of Drug Established
For personal use only SAFETY PROFILE OF DRUG ESTABLISHED 45 HUMAN CLINICAL STUDIES OF ISLA-101 COMPLETED IN OTHER INDICATIONS 4 2 Canada EU Verified as safe in 1 humans by multiple 1 Asia 39 Middle regulators in other US East clinical indications 3 Australia & NZ ISLAND PHARMACEUTICALS LIMITED 23 IN
Slide 25: ISLA-101 Accelerated Timeline FY22
For personal use only ISLA-101 ACCELERATED TIMELINE FY22 LEVERAGING THE ESTABLISHED SAFETY PROFILE OF ISLA-101 Millions of dollars Significant near-term, value accretive news flow anticipated during and years saved development Completed prior to FY21 H1 FY22 H2 FY22 H1 FY23 IPO ü Discovery ü ASX IPO
Slide 26: Drug Development Pipeline
For personal use only DRUG DEVELOPMENT PIPELINE Stage of Development Program Indication Preclinical Phase I Phase II Phase III FDA Review Dengue (PEACH) To be initiated ISLA-101 Other mosquito (or vector) borne diseases Monash TBD Collaboration Griffith TBD Collaboration ISLAND PHARMACEUTICALS LIMIT
Slide 27: What Is a Challenge Study?
For personal use only WHAT IS A CHALLENGE STUDY? HUMAN CHALLENGE STUDIES HAVE CONTRIBUTED VITAL SCIENTIFIC KNOWLEDGE • In human challenge trials, participants are Island Pharmaceuticals will work with Walter Reed intentionally challenged with an infectious Army Medical Center on its "virus challenge
Slide 28: Clinical Development Program
For personal use only CLINICAL DEVELOPMENT PROGRAM INITIAL FOCUS ON BRINGING A DENGUE FEVER DRUG TO MARKET Activities to derisk Island’s Shortened timeframe for Investigational New Drug (IND) Phase II trials application Phase IIa Phase II/III New Drug ü Pre-IND IND Dengue fever Dengue fever Approval
Slide 29: Phase II Dengue (PEACH) Trial Study in Detail
PHASE II DENGUE (PEACH) TRIAL STUDY IN DETAIL For personal use only “PEACH" STUDY- A PHASE II, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY FOR THE PROPHYLACTIC EXAMINATION OF AN ANTIVIRAL IN A DENGUE CHALLENGE MODEL Administer ISLA-101 daily Phase II trial protocol Up to 4 cohorts/4 arms Incl
Slide 30: Priority Review Voucher Eligibility
For personal use only PRIORITY REVIEW VOUCHER ELIGIBILITY Recent PRV acquisitions • ISLA-101 is eligible for Neglected Tropical Date Acquired by Value Disease designation for the treatment of Q3 2019 Astra Zeneca US$95m dengue fever Q4 2019 Confidential US$95m • This designation means ISLA-101 has t
Slide 31: Commercial Opportunity
For personal use only COMMERCIAL OPPORTUNITY Prophylactic for National Government Priority Review Military travelers outbreaks Stockpiles Voucher Tropical area travellers opportunity: Endemic area opportunity: Military opportunity: • Annual market many millions of • Isla is partnering with Army (CRA
Slide 32: Contact
For personal use only David Foster Chief Executive Officer & Executive Director david@islapharma.com Island Pharmaceuticals www.islapharma.com Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia Limited ISLAND PHARMACEUTICALS LIMITED 31 Investor INVESTOR Presentation PRESENTAT
Slide 33: Appendix
For personal use only Appendix ISLAND PHARMACEUTICALS LIMITED 32 Investor INVESTOR Presentation PRESENTATION –– October 2021 OCTOBER 2021
Slide 34: Intellectual Property
For personal use only INTELLECTUAL PROPERTY • PCT/AU2014/050017, filed 16 April 2014 In-licensed • National stage applications underway/filed in Australia, Brazil, Canada, Singapore & US patents • Issued patents in Australia, Brazil, Singapore and US • Potential for new patents • Investigator Brochu
Slide 35: ISLA-101 Protects Human Cell Culture from Dengue
ISLA101 PROTECTS HUMAN CELL CULTURE For personal use only FROM DENGUE 1000 000 • In pre-clinical work, ISLA-101 has been 100 000 specifically shown to suppress the ability of dengue to infect human cells RNA copies (no.) 10 000 • Potential role as both preventive and 100 treatment, enabling multiple
Slide 36: Protects Cells from Infection by Many Viruses
PROTECTS CELLS FROM INFECTION BY MANY For personal use only VIRUSES Proven in: Zika Chikungunya • Dengue 1 • Dengue 2 • Dengue 3 • Dengue 4 • Zika • West Nile • Chikungunya • Yellow Fever • Importantly, ISAL-101 showed very a strong dose response in decreasing viral load • This has established comme
Slide 37: Prevents Animal Deaths from Lethal Dengue
PREVENTS ANIMAL DEATHS FROM LETHAL For personal use only DENGUE Isla- 101 has also been shown to be protective in animal models of both dengue and Zika Virus. Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model). Fraser et al. J. Infect. Dis 2014 IS
Slide 38: Provides Protection Against Infection of Human Cells
PROVIDES PROTECTION AGAINST INFECTION For personal use only OF HUMAN CELLS DENV2: PBMC infection • Freshly isolated human PFU/ML PBMCs protected from infection with dengue 2 virus in a dose dependent EC50 = 0.81 μM fashion Fraser et al. J. Infect. Dis 2014 ISLAND PHARMACEUTICALS LIMITED 37 Investor
Slide 39: Platform Strategy: Multiple Shots on Goal
For personal use only PLATFORM STRATEGY: MULTIPLE SHOTS ON GOAL TARGETS • Tropical diseases with no existing therapies • Prophylactic or therapeutic trial potential ISLAND PHARMACEUTICALS LIMITED 38 Investor INVESTOR Presentation PRESENTATION –– October 2021 OCTOBER 2021
Slide 40: Board of Directors
For personal use only BOARD OF DIRECTORS ISLAND IS LED BY A HIGHLY CAPABLE, EXPERIENCED MANAGEMENT TEAM, BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD WITH EXTENSIVE EXPERTISE IN DRUG REPURPOSING AND DEVELOPMENT, INFECTIOUS DISEASES AND EXECUTING SUCCESSFUL COMMERCIAL TRANSACTIONS. Dr. Paul MacLe
Slide 41: Scientific Advisory Board
For personal use only SCIENTIFIC ADVISORY BOARD HEAVYWEIGHT ADVISORS WITH GLOBAL PEDIGREE Assoc. Prof. Leigh Farrell Dr. Simon Tucker Prof. Stephen Thomas MD • Former Vice President of Business Development • Former Vice President of Research at Biota • International leadership role as Lead Principal
Slide 42: Contact
For personal use only David Foster Chief Executive Officer & Executive Director david@islapharma.com Island Pharmaceuticals www.islapharma.com Registered office: Suite 201, 697 Burke Rd, Camberwell VIC 3124, Australia Approved for release LIMITED by Paul MacLeman Limited ISLAND PHARMACEUTICALS 41 In
Island Pharmaceuticals — Non-Deal Roadshow (October 2021) on 6ix